Literature DB >> 10211752

Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell lines.

A Haack1, C Schmitt, W Poller, J Oldenburg, P Hanfland, H H Brackmann, R Schwaab.   

Abstract

Transient expression of full-length wild-type (wt) and a new B-domain truncated (deltaB) FVIII has been investigated in three eukaryotic cell lines (HEK-293, COS, CHO). When expressed in CHO cells, both FVIII proteins reached the same peak antigen levels, whereas in HEK-293 and COS cells those of FVIII/deltaB were up to sixfold those of FVIII/wt. Investigation of specific activity of the recombinant FVIII proteins using a chromogenic and a one-stage assay in addition to the FVIII-antigen ELISA revealed large variations: In HEK-293 cells specific activity of FVIII/deltaB measured with both assays was higher than that of FVIII/wt. In COS cells specific activity of both FVIII proteins was higher measured in the one-stage assay than in the chromogenic assay. In CHO cells both FVIII proteins had similar specific activity in each assay. In summary, expression kinetics and specific activity of conditioned medium vary depending on cell type used.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211752     DOI: 10.1007/s002770050486

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  3 in total

Review 1.  Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.

Authors:  Massimo Morfini; Stefano Gherardini
Journal:  Ther Adv Hematol       Date:  2018-06-05

2.  Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII.

Authors:  Kamilla Swiech; Amine Kamen; Sven Ansorge; Yves Durocher; Virgínia Picanço-Castro; Elisa M S Russo-Carbolante; Mário S A Neto; Dimas T Covas
Journal:  BMC Biotechnol       Date:  2011-11-24       Impact factor: 2.563

3.  About making a CHO production cell line "research-friendly" by genetic engineering.

Authors:  Bernd Voedisch; Agnès Patoux; Jildou Sterkenburgh; Mirjam Buchs; Emily Barry; Cyril Allard; Sabine Geisse
Journal:  BMC Proc       Date:  2011-11-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.